Efficacy and Safety Study of ABX464 as Maintenance Therapy in Patients With Moderate to Severe Ulcerative Colitis
Study sponsor: Abivax S.A. · ABVX
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2023-02-23Actual
Enrollment · participants217Actual
Source updated2026-05-06Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.